Vanessa Malier - Nov 9, 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role
Director
Signature
/s/ Brian Burkavage, Attorney-in-Fact for Vanessa Malier
Stock symbol
IOBT
Transactions as of
Nov 9, 2021
Transactions value $
$4,550,000
Form type
4
Date filed
11/12/2021, 03:16 PM
Previous filing
Nov 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction IOBT Common Stock Conversion of derivative security +796 K 796 K Nov 9, 2021 See footnote F1, F2
transaction IOBT Common Stock Conversion of derivative security +268 K 268 K Nov 9, 2021 See footnote F1, F3
transaction IOBT Common Stock Purchase $2.28 M +163 K +20.41% $14.00 959 K Nov 9, 2021 See footnote F2
transaction IOBT Common Stock Purchase $2.28 M +163 K +60.64% $14.00 430 K Nov 9, 2021 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOBT Series C Preferred Stock Conversion of derivative security $0 -63.4 K -100% $0.00 0 Nov 9, 2021 Common Stock 796 K See footnote F1, F2
transaction IOBT Series C Preferred Stock Conversion of derivative security $0 -21.3 K -100% $0.00 0 Nov 9, 2021 Common Stock 268 K See footnote F1, F3

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
F2 The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
F3 The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.